A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence - sprookjes - yvandenbroek - TriplyDB

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

http://www.wikidata.org/entity/Q28295210

about

Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?Intestinal microbiota in functional bowel disorders: a Rome foundation report Irritable bowel syndrome Small intestinal bacterial overgrowth in patients with irritable bowel syndrome Use of rifaximin in gastrointestinal and liver diseases Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials Profile of rifaximin and its potential in the treatment of irritable bowel syndrome Abdominal bloating: pathophysiology and treatment Methanogens, methane and gastrointestinal motility Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome.Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome.Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.Review article: the treatment of functional abdominal bloating and distension.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome.Does oral α-galactosidase relieve irritable bowel symptoms?Gas and Bloating.An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting.Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.Recent advances in pharmacological treatment of irritable bowel syndrome.Irritable bowel syndrome: a review article.Irritable bowel syndrome: a clinical review Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Bloating and functional gastro-intestinal disorders: where are we and where are we going?The treatment of irritable bowel syndrome Do probiotics improve symptoms in patients with irritable bowel syndrome?Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Rifaximin treatment for symptoms of irritable bowel syndrome.Antibiotics for irritable bowel syndrome: rationale and current evidence.Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options.Case studies of antibiotic therapy in the management of functional gastrointestinal disorders.Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome.Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.

P2860

Q21261900-7DD1ADD1-6F6D-4631-B7A9-7F4DD558A0A1 Q24631357-A9B06B8A-4D47-4EEC-99F8-0CD4A48D24CC Q24670113-992754C1-7A6D-4274-BD29-1700ECBC416B Q24674609-9C32B0DA-9F51-4744-8C32-D40F743F6A42 Q26740201-B4211D2B-3373-4D54-8871-7BF5EFF120C7 Q26771942-2134A0C8-24A9-4AD6-8005-0E669991977E Q26772962-A932CD02-B69A-4375-8FCE-57751BCB2CC8 Q26829363-025589F2-FFA1-4D28-BC2D-D354ADF6829D Q26851622-FDFD5076-41FA-4865-8349-6F3A5675DE7B Q27693339-855D4C53-CC27-4D02-A35C-EF7D6AFB5885 Q31142368-03AB02DA-BD9F-4C1B-8B90-CD6013795949 Q33448962-2F11B41B-70D7-41A9-919E-03F945BF392F Q33449179-D4AF0DD0-A715-42C3-A5A8-617E12E99A86 Q33449885-0F9E867D-6496-4440-9BAE-0A52BA723298 Q33450132-8C65BA87-4249-48D3-B48E-2F894F3659B7 Q33456102-A0EB1DA3-7BAD-42F4-AB9F-008B53E7FF37 Q33457676-8458DADC-EE26-43AF-9050-7A81AB907E29 Q33465479-E6955AB5-1497-4080-9DB0-C6CF31739C8C Q33470091-E67BCA06-653A-4750-8980-FA536D66F54D Q33667183-52A76B16-6870-45B6-B0D2-2E5B96377C33 Q33688135-8BEDB860-515F-46B4-B127-DB7B763E7B2C Q33916182-4C98AD01-228C-45BA-A06A-6A7D01EDEAF7 Q33939802-D81B5097-A0AB-46E2-8E18-07290287C0FD Q33954221-0E11283F-7BB6-4E6E-ADDC-13DF5EC0C050 Q33958853-9EDA9EB5-41A6-4509-AD1D-E9EA96430988 Q34134491-99A2EE18-19B9-4D2C-941C-5B1121B25242 Q34168517-63DEEB2F-A14D-4A64-A147-9606478753CE Q34170707-175839B4-DC25-4F94-B1BA-CB022FCD920A Q34248518-468DE3C8-C7DF-49F4-828A-78C8802869DE Q34323319-99C413B8-8348-49FF-921F-6F65928CD81F Q34366956-55BE9CB8-855B-4807-9C98-EC6780310F90 Q34409009-FEC080C5-5F5F-4B2F-B429-C44F977CE9E8 Q34409031-D7643089-7CDD-4826-B727-83BDCB641137 Q34409219-45DD4C5C-41F3-4058-B5B6-73A971CA8E70 Q34588803-A502B8ED-6DDD-4135-BB07-B9342AD3816E Q34642080-A60688E0-DFB1-4EEC-8FB6-5B045E782E92 Q34960559-8EEB707F-F117-48FC-ABE8-B6CA51286323 Q34985950-343D047B-174C-4480-B006-EC544D2DB963 Q35007544-1BE8ED94-9B64-4FF4-8333-E4113A2D006B Q35018460-D941431D-8F41-4F76-881E-E76DAD670DB5

P2860

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

http://www.wikidata.org/entity/Q28295210

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A randomized double-blind plac ...... ominal bloating and flatulence

@ast

A randomized double-blind plac ...... ominal bloating and flatulence

@en

A randomized double-blind plac ...... ominal bloating and flatulence

@nl

type

label

A randomized double-blind plac ...... ominal bloating and flatulence

@ast

A randomized double-blind plac ...... ominal bloating and flatulence

@en

A randomized double-blind plac ...... ominal bloating and flatulence

@nl

prefLabel

A randomized double-blind plac ...... ominal bloating and flatulence

@ast

A randomized double-blind plac ...... ominal bloating and flatulence

@en

A randomized double-blind plac ...... ominal bloating and flatulence

@nl

P1433

Q28295210-66E7CF98-BD6F-4DD4-A09F-42BAB33987B5

P1476

Q28295210-AB4679B0-E6FA-4D1F-9F89-3E947676E555

P2093

Q28295210-4FC77E0F-CFBF-430F-99A1-4E4FF2AD7F98

Q28295210-A09C8AE6-9F3F-42CD-B484-BC17DD53C112

Q28295210-A8A4A809-524E-4B5D-9316-0D1E067164D3

Q28295210-CDB2CF56-E2D5-44BD-A057-8123FA509BE4

Q28295210-F16CBA5D-1EBA-40B5-A78D-94EDC253FBF3

Q28295210-F74CAB8F-EC3E-425C-98D8-E0DBEC63E090

P2860

Q28295210-0251FD4E-869C-4E6A-B779-C1D2A3CEDEDE

Q28295210-404C4A77-07C5-4000-8C7A-39F69A13CA5E

Q28295210-5AF3173B-696E-44EE-9161-5E144F264913

Q28295210-6F0839A3-2724-4540-9F1B-D7CD00C850BF

Q28295210-7F831AB9-0816-4B02-BBC9-B9F4796542E2

Q28295210-8784ADF8-D9B7-4354-AB09-0A9F9338E920

Q28295210-8C1FE6A8-BBD9-4345-B53C-67605AAC7BE0

Q28295210-901E54DA-FDD9-4D79-8473-BC767DDAB971

Q28295210-909DCDD9-CAA6-451E-A14F-04303EECCCA1

Q28295210-9284CFC7-7C53-413D-90E9-46BD2EFBDD8A

P304

Q28295210-9E29E51D-D9F9-432D-8F55-6F96F42B207E

P31

Q28295210-13CF37C8-53D7-4C46-A5A5-83FEC642871F

P3181

Q28295210-B67405F9-C777-40FB-9439-951C791C11E5

P356

Q28295210-506D48C4-B72D-4E99-BF4F-FA70971AD617

P407

Q28295210-4735A1F4-19BB-4572-A695-0B29768FC061

P433

Q28295210-74FFA760-C36D-4C57-8C85-FCD377892893

P478

Q28295210-55F421B8-0ECD-44BA-A64A-D991D542A16C

P577

Q28295210-A352FCC0-B18F-4A44-A8FF-A641A59BDA7C

P5875

Q28295210-002E10D9-7DED-4399-95A5-A4D6B64D36C3

P698

Q28295210-A0671247-185D-4C6E-92E8-7A4A1C703622

P921

Q28295210-67705A0F-3338-486B-945F-6C971EB8A686

Q28295210-BE326856-37D8-4A03-804A-5C301EA01C87

Q28295210-FCBB3178-4A9E-42F7-A36F-DA2B5A2396F3

P3181

P356

J.1572-0241.2006.00458.X

P1433

The American Journal of Gastroenterology

P1476

A randomized double-blind plac ...... ominal bloating and flatulence

@en

P2093

Ala I Sharara

http://www.w3.org/2001/XMLSchema#string

Elie Aoun

http://www.w3.org/2001/XMLSchema#string

Heitham Abdul-Baki

http://www.w3.org/2001/XMLSchema#string

Ihab Elhajj

http://www.w3.org/2001/XMLSchema#string

Rawad Mounzer

http://www.w3.org/2001/XMLSchema#string

Shafik Sidani

http://www.w3.org/2001/XMLSchema#string

P2860

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.

Abnormal colonic fermentation in irritable bowel syndrome.

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.

Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.

A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome.

Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population.

P304

326-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1267757

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1572-0241.2006.00458.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7319033

http://www.w3.org/2001/XMLSchema#string

P698

16454838

http://www.w3.org/2001/XMLSchema#string

P921